People · Operator
Named in public records as an officer, director or promoter · active 2024–2025 · Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Leegen Investment LLC | — | Other | Series B | $28.2M | $43.8M | 2024 |
| Addition Therapeutics, Inc. | — | Biotechnology | Series B | $28.0M | $107.4M | 2025 |
Jennifer Lee at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jennifer Lee on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Bisgaard | 1 | 9 |
| Jayson Punwani | 1 | 3 |
| Matthew Patterson | 1 | 3 |
| Jennifer J. Lee | 1 | 3 |
| Tommy Lee | 1 | 2 |
| Lawrence Kong | 1 | 1 |
| Laetitia Schwab | 1 | 1 |
| Ronald Park | 1 | 1 |
| Kathleen Collins | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.